Results 231 to 240 of about 7,461,141 (296)

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Clinicopathological features, morbidity and survival in gastric adenocarcinoma, with a focus on stage III: a retrospective institutional cohort analysis. [PDF]

Arq Bras Cir Dig
Pinto MF, Kassab P, Castro OAP, Mitidieri ACH.   +3 more
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Adjuvant sandwich therapy is associated with improved survival in stage III-IVA endometrial cancer: a network meta-analysis. [PDF]

J Gynecol Oncol
Chen X, Ding Y, Liao Y, Luo X, Deng T, Yang D, Liu J, Huang H.   +7 more
europepmc   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation. [PDF]

ESMO Real World Data Digit Oncol
Hwang C, Stambaugh N, Levey J, Stambaugh C, Spiegel D, Huber K.   +5 more
europepmc   +1 more source

Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study. [PDF]

Front Immunol
Kim M, Gaughan EM, Azpeitia A, Rao A, Wei ML, So A, Zhong X, Berking C, Jiang R, Dalle S, Robert C, Alam S, Davies T, Debus D, Dzienis M, Danson S, Frazer R, Gebhardt C, Geidel G, Hassel JC, Hansen I, Heppt MV, Hildebrandt L, Isaacs J, Suh KJ, Keam B, Kim YJ, Lesimple T, Saiag P, Weight R, Delibes A, Barnett R, Krepler C, Gandhi K, Qizilbash N, Shui I, Tan XL, Sullivan RJ.   +37 more
europepmc   +1 more source

Evaluating the prognostic value of estrogen receptor status in stage III MMR-proficient endometrial cancer: real-world data from an Asian population. [PDF]

Am J Cancer Res
Huang SW, Lin H, Huang CC, Ou YC, Fu HC, Tsai CC, Wang YW, Chen YY, Kuo FC, Wu CH.   +9 more
europepmc   +1 more source

Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study. [PDF]

Front Oncol
Zhao X, Wang B, Zhang Y, Li P, Liang X, Gong Q, Tian L, Qin T, Chen X, Li Z, Nie P, Zhang Y, Ye Y.   +12 more
europepmc   +1 more source

Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01). [PDF]

Cancer Immunol Res
Liu C, Du Y, Han D, Li B, Liu X, Fan B, Sun H, Fu C, Xu L, Dai T, Huang W.   +10 more
europepmc   +1 more source